CRISPR-edited tumor-infiltrating lymphocytes are emerging as a promising alternative to CAR T-cell therapy for solid cancers.
ImmunityBio, Inc. receives a Strong Buy rating, driven by ANKTIVA's compelling clinical data and major regulatory catalysts ...
MedPage Today on MSN
No Prostate Cancer Survival Benefit With More Extensive Lymph Node Assessment
Long-term follow-up consistent with earlier report, a hint of benefit in high-grade diseas ...
Final results from a landmark EORTC randomized trial with more than 20 years of follow-up show that irradiation of the ...
Immunotherapy with and without radiotherapy following the diagnosis of bone metastasis for stage 4 non-small cell carcinoma. Efficacy and safety of nivolumab plus chemotherapy versus chemotherapy ...
Cervical cancer is among the most common malignancies affecting women worldwide. In 2020 alone, approximately 600,000 women were diagnosed with this disease, and over 314,000 died from it. In 99% of ...
Lymphocyte-depleted Hodgkin’s lymphoma (LDHL) is a rare subtype of Hodgkin’s lymphoma, a cancer that develops in the lymphatic system. Hodgkin’s lymphoma (HL) is an uncommon cancer of the lymphatic ...
Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum Data for 239 patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results